{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:29:14Z","timestamp":1787318954054,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fetal acetylcholine receptor antibody-associated disorders (FARAD), caused by in utero exposure to maternal antibodies directed against the fetal acetylcholine receptor (AChR), is a rare condition occurring in newborns of myasthenic mothers. Only two cases of FARAD children born to asymptomatic mothers are published.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>We report a completely asymptomatic mother of two FARAD children presenting exclusively with positive AChR antibodies. After birth, the first child needed intensive care therapy due to generalized hypotonia, respiratory problems, dysphagia, necessitating tube feeding and gastrostomy. FARAD was suspected because of ptosis, a hypomimic face, and confirmed by increased AChR antibodies in the mother. The mother became pregnant again 2 years later. Since FARAD is likely to reoccur and it is known that intensity of maternal myasthenia gravis treatment determines postnatal outcome, monthly intravenous immunoglobulin (IVIG) therapy was started at 12 weeks gestational age. The second child needed a short mask ventilation for initial stabilization at birth, but her muscle weakness improved rapidly and tube feeding was not necessary. Similar to her sister a tent-shaped mouth and a somewhat myopathic face persisted, but motor milestones were reached in time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These observations highlight that FARAD is an important differential diagnosis of genetically determined congenital neuromuscular disorders even in asymptomatic mothers, and that IVIG therapy during the pregnancy has the potential to improve the outcome of the children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42466-023-00280-6","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T20:02:16Z","timestamp":1698264136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Maternal immunoglobulin treatment can reduce severity of fetal acetylcholine receptor antibody-associated disorders (FARAD)"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9484-1597","authenticated-orcid":false,"given":"Matthias","family":"Wassenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"M\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun H.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"280_CR1","doi-asserted-by":"crossref","unstructured":"Allen, N. M. (2023). The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD). Brain, awad153.","DOI":"10.1016\/j.nmd.2023.07.445"},{"key":"280_CR2","doi-asserted-by":"publisher","first-page":"S190","DOI":"10.1016\/j.nmd.2019.06.536","volume":"29","author":"D Nguyen","year":"2019","unstructured":"Nguyen, D., Botez, S., & Nguyen, C. (2019). MYASTHENIA GRAVIS. Neuromuscular Disorders, 29, S190.","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"280_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(20000501)92:1<1::AID-AJMG1>3.0.CO;2-H","volume":"92","author":"LA Brueton","year":"2000","unstructured":"Brueton, L. A., Huson, S. M., Cox, P. M., Shirley, I., Thompson, E. M., Barnes, P. R. J., Price, J., Newsom-Davis, J., & Vincent, A. (2000). Asymptomatic maternal myasthenia as a cause of the Pena-Shokeir phenotype. American Journal of Medical Genetics, 92(1), 1\u20136.","journal-title":"American Journal of Medical Genetics"},{"key":"280_CR4","doi-asserted-by":"crossref","unstructured":"Hacohen, Y., Jacobson, L. W., Byrne, S., Norwood, F., Lall, A., Robb, S., Dilena, R., Fumagalli, M., Born, A. P., Clarke, D., Lim, M., Vincent, A., & Jungbluth, H. (2014). Fetal acetylcholine receptor inactivation syndrome: A myopathy due to maternal antibodies. Neurology(R) Neuroimmunology & Neuroinflammation, 2(1), e57.","DOI":"10.1212\/NXI.0000000000000057"},{"issue":"7","key":"280_CR5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1212\/WNL.0000000000002382","volume":"86","author":"NM Allen","year":"2016","unstructured":"Allen, N. M., Hacohen, Y., Palace, J., Beeson, D., Vincent, A., & Jungbluth, H. (2016). Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome. Neurology, 86(7), 692\u2013694.","journal-title":"Neurology"},{"key":"280_CR6","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3389\/fneur.2020.00554","volume":"11","author":"NE Gilhus","year":"2020","unstructured":"Gilhus, N. E. (2020). Myasthenia Gravis can have consequences for pregnancy and the developing child. Frontiers in Neurology, 11, 554.","journal-title":"Frontiers in Neurology"},{"issue":"24","key":"280_CR7","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1212\/01.wnl.0000336929.38733.7a","volume":"71","author":"M Oskoui","year":"2008","unstructured":"Oskoui, M., Jacobson, L., Chung, W. K., Haddad, J., Vincent, A., Kaufmann, P., & De Vivo, D. C. (2008). Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis. Neurology, 71(24), 2010\u20132012.","journal-title":"Neurology"},{"key":"280_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jns.2017.10.037","volume":"383","author":"J Gamez","year":"2017","unstructured":"Gamez, J., Salvado, M., Casellas, M., Manrique, S., & Castillo, F. (2017). Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy. Journal of the Neurological Sciences, 383, 118\u2013122.","journal-title":"Journal of the Neurological Sciences"},{"issue":"6","key":"280_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.pedneo.2021.05.020","volume":"62","author":"S Iijima","year":"2021","unstructured":"Iijima, S. (2021). Clinical and pathophysiologic relevance of autoantibodies in neonatal myasthenia gravis. Pediatrics & Neonatology, 62(6), 581\u2013590.","journal-title":"Pediatrics & Neonatology"},{"issue":"6","key":"280_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.nmd.2012.01.002","volume":"22","author":"A D\u2019Amico","year":"2012","unstructured":"D\u2019Amico, A., Bertini, E., Bianco, F., Papacci, P., Jacobson, L., Vincent, A., & Mercuri, E. (2012). Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis: A case report. Neuromuscular Disorders, 22(6), 546\u2013548.","journal-title":"Neuromuscular Disorders"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-023-00280-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-023-00280-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-023-00280-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:11:42Z","timestamp":1700266302000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-023-00280-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1186\/s42466-023-00280-6","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient is the legal guardian of the two children. The patient has given a written consent for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}